ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.8463) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Trading Up 0.7%

Shares of NASDAQ:AVBP opened at $22.18 on Tuesday. The stock has a market capitalization of $980.36 million, a P/E ratio of -5.03 and a beta of 0.98. The stock’s 50-day moving average price is $22.99 and its 200-day moving average price is $21.27. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $27.22.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AVBP. Cantor Fitzgerald assumed coverage on ArriVent BioPharma in a report on Monday, December 22nd. They set an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Oppenheimer reissued an “outperform” rating and set a $50.00 price objective (up from $44.00) on shares of ArriVent BioPharma in a research note on Friday, March 6th. Finally, HC Wainwright raised their target price on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.67.

Institutional Trading of ArriVent BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of AVBP. Russell Investments Group Ltd. grew its holdings in shares of ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after acquiring an additional 2,047 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of ArriVent BioPharma by 31.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after purchasing an additional 609 shares during the period. Group One Trading LLC purchased a new position in shares of ArriVent BioPharma in the 4th quarter valued at approximately $57,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ArriVent BioPharma by 696.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,258 shares of the company’s stock valued at $60,000 after purchasing an additional 2,849 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of ArriVent BioPharma by 571.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,669 shares of the company’s stock valued at $145,000 after purchasing an additional 5,676 shares in the last quarter. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.